YOKNEAM, Israel–(BUSINESS WIRE)–ASCRS Booth #2311– Lumenis, Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, will present interim results of a multicenter prospective clinical trial designed to study the safety and efficacy of Optimal Pulse Technology (OPTTM), the next generation of Intense Pulse Light (IPL) technology, for treating Dry Eye Disease (DED). Data from the trial, being led by Steven J. Dell, MD, of Dell Laser Cons
NEW ORLEANS — At the Ophthalmology Innovation Summit, Amar Sawhney, PhD, chairman, CEO and president of Ocular Therapeutix, discusses the company’s therapeutics pipeline and progress in approvals and clinical trials.
NEW ORLEANS — At the Ophthalmology Innovation Summit, Andrew Chang, general manager and vice president U.S. surgical for Bausch + Lomb, discusses the recently announced partnership with IBM, as well as other innovations taking place at the American Society of Cataract and Refractive Surgery meeting.
NEW ORLEANS — At the Ophthalmology Innovation Summit, Tom Mitro, president and COO of Aerie Pharmaceuticals, discusses the current clinical trial status of Roclatan and Rhopressa.
NEW ORLEANS — At the Ophthalmology Innovation Summit, Nick Tarantino, OD, chief of global clinical research and regulatory affairs officer for AcuFocus, gives an update on the launch of the Kamra corneal inlay and the IC-8 small aperture IOL.
NEW ORLEANS — At the Ophthalmology Innovation Summit, John Berdahl, MD, discusses the use of a new orally administered conscious sedation formulation for cataract surgery from Imprimis Pharmaceuticals.